Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer
Authors:
- 18 July 2006
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 36 (8) , 566-573
Abstract
Background Suppressive thyroid hormone therapy is generally a lifelong treatment for patients with differentiated thyroid cancer (DTC). However, long‐standing thyrotropin (TSH) suppression is a risk factor for osteoporosis. Osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) are central regulators of bone turnover. The aim was to analyze the effects of a suppressive thyroid hormone therapy in males with DTC on the OPG/RANKL system and on bone metabolism.Patients and methods The OPG and soluble RANKL (sRANKL) were determined in 40 men (mean age, 53·2 years) with DTC on suppressive thyroid hormone therapy (TSH; 0·053 ± 0·037 mU L−1, duration 5·7 ± 4·4 years) and 120 healthy controls matched for age. The markers of bone metabolism were C‐terminal telopeptide of type I collagen in serum (sCTx) and osteocalcin (OC).Results The control group had OPG values (mean ± SD) of 1·9 ± 1·0 pmol L−1 and sRANKL values of 0·40 ± 0·62 pmol L−1. In patients with DTC, results for OPG were 3·03 ± 1·04 pmol L−1 (P < 0·05) and for sRANKL were 0·13 ± 0·16 pmol L−1 (P < 0·05). The control group presented values for sCTx of 2669 ± 1132 pmol L−1 and for OC of 17·89 ± 6·5 ng mL−1. Patients with DTC on suppressive thyroid hormone therapy had increased sCTx values of 3810 ± 2020 pmol L−1 (P = 0·03) but comparable OC values of 19·21 ± 7·67 ng mL−1 (NS).Conclusion Suppressive thyroid hormone therapy in men with DTC increased bone degradation and induced significant changes in the OPG/RANKL system. These changes include, besides the risk of osteoporosis, possible negative effects on the vascular function and an increased risk of cardiovascular disease.Keywords
This publication has 53 references indexed in Scilit:
- Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinomaEndocrine-Related Cancer, 2005
- AACE/AAES MEDICAL/SURGICAL Guidelines for Clinical Practice: Management of Thyroid CarcinomaEndocrine Practice, 2001
- Risk for Fracture in Women with Low Serum Levels of Thyroid-Stimulating HormoneAnnals of Internal Medicine, 2001
- Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancerThe Journal of Clinical Endocrinology & Metabolism, 1996
- Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid AssociationArchives of internal medicine (1960), 1996
- The isoform‐specific expression of the tri‐iodothyronine receptor in osteoblasts and osteoclastsEuropean Journal of Clinical Investigation, 1996
- Levothyroxine therapy and osteoporosis. An end to the controversy?Archives of internal medicine (1960), 1995
- Detrimental skeletal effects of thyrotropin suppressive doses of thyroxine: fact or fantasy?The Journal of Clinical Endocrinology & Metabolism, 1994
- Biochemical assessment of bone loss in patients on long-term thyroid hormone treatmentBone and Mineral, 1992
- Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal womenJAMA, 1988